Assignee
CYTEIR THERAPEUTICS INC
US·8 granted patents·9 pending applications·24 citations·filing 2018–2024
Top patents by PatentIndex Score
17 records- 0195US11084812B2RAD51 inhibitorsCYTEIR THERAPEUTICS INC·Filed 2020·Granted Aug 10, 2021·4 cites·23 claims
- 0294US10336746B1RAD51 inhibitorsCYTEIR THERAPEUTICS INC·Filed 2018·Granted Jul 2, 2019·7 cites·4 claims
- 0393US10590122B2RAD51 inhibitorsCYTEIR THERAPEUTICS INC·Filed 2018·Granted Mar 17, 2020·7 cites·19 claims
- 0490US11247988B2RAD51 inhibitorsCYTEIR THERAPEUTICS INC·Filed 2020·Granted Feb 15, 2022·2 cites·33 claims
- 0589US11607404B2Combinations of RAD51 and PARP inhibitorsCYTEIR THERAPEUTICS INC·Filed 2020·Granted Mar 21, 2023·3 cites·12 claims
- 0686US2025136591A1Rad51 inhibitorsCYTEIR THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0780US11291655B2RAD51 inhibitorsCYTEIR THERAPEUTICS INC·Filed 2018·Granted Apr 5, 2022·1 cites·20 claims
- 0880US2024360120A1Rad51 inhibitorsCYTEIR THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0973US2022056022A1Rad51 inhibitorsCYTEIR THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1072US11932636B2RAD51 inhibitorsCYTEIR THERAPEUTICS INC·Filed 2021·Granted Mar 19, 2024·0 cites·25 claims
- 1172US2025082614A1Methods of using rad51 inhibitors for treatment of pancreatic cancerCYTEIR THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1262US12064419B2Methods of using RAD51 inhibitors for treatment of pancreatic cancerCYTEIR THERAPEUTICS INC·Filed 2020·Granted Aug 20, 2024·0 cites·16 claims
- 1361US2025051294A1Method for preparing cyclohexyl thiazolyl phenyl carbamateCYTEIR THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1460US2025186404A1Methods of using a (thiazolyl)benzenesulfonamide derivativeCYTEIR THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1560US2025276952A14-aminophenyl-thiazole derivatives and methods of use thereofCYTEIR THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1659US2025268869A1Methods of using a (thiazolyl)benzenesulfonamide derivativeCYTEIR THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1752US2021275503A1Targeting homologous recombination: a new sythetic lethal therapeutic paradigmCYTEIR THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →